Recurrent Chest Pain on Clopidogrel: What the Genotype Explained After the Fact
His clopidogrel failed clinically before anyone tested why. The genotype explained it after the fact; the real decision is which drug replaces it in a man whose job puts him behind the wheel eleven hours at a stretch.
R.N., a 63-year-old man, has driven long-haul freight for almost thirty years, and for the past four months he has also been driving his mother to dialysis three times a week since her dementia made it unsafe for her to manage the appointments herself. He has hypertension, managed on lisinopril for over a decade, and otherwise no cardiac history before this. Three weeks ago he had an NSTEMI, was found to have a critical lesion in the mid-LAD, and received a drug-eluting stent; he was discharged on aspirin and clopidogrel and went back on the road within a week, against medical advice but not against his own sense of what his routes and his mother both required of him.
He is back now with recurrent substernal chest pressure on two occasions this week, both resolving with rest, both accompanied by a mildly elevated troponin that his cardiologist read as probable in-stent thrombosis rather than a new lesion. That reading prompted reflex CYP2C19 genotyping, which came back poor metabolizer — two loss-of-function alleles, meaning clopidogrel was never being converted to its active metabolite in meaningful quantity, whatever his actual adherence to the prescribed dose had been. The clinical picture had already answered the question the genotype later confirmed: a demonstrated breakthrough thrombotic event on a P2Y12 inhibitor that current pharmacogenomic guidance would have flagged as inadequate from the start, had anyone tested for it before rather than after. His route schedule, largely overnight and interstate, means any replacement therapy also has to survive being taken on a truck-stop routine rather than a fixed daily rhythm.
At the recurrent-symptoms visit
This isn't a theoretical genotype flag — he had a clinical thrombotic event on clopidogrel, and the genotype explains why. CPIC guidance is direct here: poor and intermediate metabolizers undergoing PCI for ACS should be switched to prasugrel or ticagrelor if there's no contraindication, and he has none of the classic ones. Prasugrel, 60 mg loading dose now — the switch is being made in the acute setting, so it gets loaded regardless of when his last clopidogrel dose was — then 10 mg once daily.
I'm not arguing with the genotype. I'm asking whether the practical realities of his job change which of the two alternatives makes more sense. He's behind the wheel for eleven-hour stretches on irregular schedules. Ticagrelor's dyspnea side effect worries me specifically in that context — a driver who feels short of breath at highway speed is a different problem than one who feels it at home.
His weight and age don't put him in either drug's caution categories, so this isn't really a safety argument on my end — it's a practicality one, and I don't think it should outweigh the stronger diabetic-magnitude data prasugrel has shown, since he isn't diabetic anyway. I raise it because it's real, not because I think it should decide this.
Agreed that it's not a safety argument, and I think it actually reinforces the choice rather than complicating it — prasugrel's once-daily dosing and absence of a dyspnea signal both fit his schedule better than ticagrelor's twice-daily regimen would. Prasugrel 10 mg daily, continuing aspirin 81 mg. The larger unresolved question, for the practice generally, is whether ACS patients undergoing PCI should get point-of-care CYP2C19 genotyping up front rather than only after a breakthrough event makes us look for it.
Switched to prasugrel with a 60 mg loading dose, then 10 mg daily, with continued aspirin 81 mg. Follow-up in 2 weeks to confirm resolution of symptoms.
Agreed without real disagreement on the switch itself; the standing question raised and left open was procedural rather than pharmacologic — whether upfront genotyping before the first P2Y12 prescription, rather than reactive testing after a stent-thrombosis scare, should become routine practice for ACS patients undergoing PCI at this center.